Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?

We discuss the currently available data on the use of the prostacyclin mimetic selexipag in children and adolescents with pulmonary arterial hypertension (PAH). Future indications may include transitioning from intravenous prostacyclin/prostacyclin analog to oral selexipag, and vice versa, or adding...

Descripción completa

Detalles Bibliográficos
Autores principales: Koestenberger, Martin, Hansmann, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Research Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161208/
https://www.ncbi.nlm.nih.gov/pubmed/30260767
http://dx.doi.org/10.1177/2045894018793580
_version_ 1783358940869820416
author Koestenberger, Martin
Hansmann, Georg
author_facet Koestenberger, Martin
Hansmann, Georg
author_sort Koestenberger, Martin
collection PubMed
description We discuss the currently available data on the use of the prostacyclin mimetic selexipag in children and adolescents with pulmonary arterial hypertension (PAH). Future indications may include transitioning from intravenous prostacyclin/prostacyclin analog to oral selexipag, and vice versa, or adding selexipag as a third oral PAH-targeted agent in children not responding well to dual PAH therapy.
format Online
Article
Text
id pubmed-6161208
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-61612082018-10-01 Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension? Koestenberger, Martin Hansmann, Georg Pulm Circ Research Letter We discuss the currently available data on the use of the prostacyclin mimetic selexipag in children and adolescents with pulmonary arterial hypertension (PAH). Future indications may include transitioning from intravenous prostacyclin/prostacyclin analog to oral selexipag, and vice versa, or adding selexipag as a third oral PAH-targeted agent in children not responding well to dual PAH therapy. SAGE Publications 2018-09-27 /pmc/articles/PMC6161208/ /pubmed/30260767 http://dx.doi.org/10.1177/2045894018793580 Text en © The Author(s) 2018 http://creativecommons.org/licenses/by-nc/4.0/ Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle Research Letter
Koestenberger, Martin
Hansmann, Georg
Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?
title Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?
title_full Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?
title_fullStr Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?
title_full_unstemmed Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?
title_short Should we use the oral selective IP receptor agonist selexipag off-label in children with pulmonary arterial hypertension?
title_sort should we use the oral selective ip receptor agonist selexipag off-label in children with pulmonary arterial hypertension?
topic Research Letter
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6161208/
https://www.ncbi.nlm.nih.gov/pubmed/30260767
http://dx.doi.org/10.1177/2045894018793580
work_keys_str_mv AT koestenbergermartin shouldweusetheoralselectiveipreceptoragonistselexipagofflabelinchildrenwithpulmonaryarterialhypertension
AT hansmanngeorg shouldweusetheoralselectiveipreceptoragonistselexipagofflabelinchildrenwithpulmonaryarterialhypertension

Ejemplares similares